Clinical and molecular approaches to individualize antihypertensive drug therapy

References

• Attwood S, Bird R, Burch K, Casadei B, Coats A, Conway J, . Within-patient correlation between the antihypertensive effects of atenolol, lisinopril and nifedipine. J Hypertens. 1994;12:1053–60.
   PubMed Web of Science ®Google Scholar
• Hiltunen TP, Suonsyrjä T, Hannila-Handelberg T, Paavonen KJ, Miettinen HE, Strandberg T, . Predictors of antihypertensive drug responses: initial data from a placebo-controlled, randomized, cross-over study with four antihypertensive drugs (The GENRES Study). Am J Hypertens. 2007;20:311–8.
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones DM, Evans JC, Larson MG, O'Donnell CJ, Roccella EJ, Levy D. Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community. Hypertension. 2000;36:594–9.
   PubMed Web of Science ®Google Scholar
• Varis J, Savola H, Vesalainen R, Kantola I. Treatment of hypertension in Finnish general practice seems unsatisfactory despite evidence-based guidelines. Blood Press. 2009;18:62–7.
   PubMed Web of Science ®Google Scholar
• Deary AJ, Schumann AL, Murfet H, Haydock SF, Foo RS, Brown MJ. Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs. J Hypertens. 2002;20:771–7.
   PubMed Web of Science ®Google Scholar
• Suonsyrjä T, Hannila-Handelberg T, Paavonen KJ, Miettinen HE, Donner K, Strandberg T, . Laboratory tests as predictors of the antihypertensive effects of amlodipine, bisoprolol, hydrochlorothiazide and losartan in men: results from the randomized, double-blind, crossover GENRES Study. J Hypertens. 2008;26:1250–6.
   PubMed Web of Science ®Google Scholar
• Laragh JH, Letcher RL, Pickering TG. Renin profiling for diagnosis and treatment of hypertension. JAMA. 1979;241:151–6.
   PubMed Web of Science ®Google Scholar
• Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, . Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med. 1993;328:914–21.
   PubMed Web of Science ®Google Scholar
• Preston RA, Materson BJ, Reda DJ, Williams DW, Hamburger RJ, Cushman WC, . Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. JAMA. 1998;280: 1168–72.
   PubMed Web of Science ®Google Scholar
• Mazeaud MM, Sang KH, Astarie C, Levenson J, Simon A, Devynck MA. Hypercholesterolemia modulates the effects of nitrendipine on blood pressure and platelet function in essential hypertension. J Cardiovasc Pharmacol. 1991; 18(Suppl 10):S46–51.
   Google Scholar
• Resnick LM, Nicholson JP, Laragh JH. Calcium, the renin-aldosterone system, and the hypotensive response to nifedipine. Hypertension. 1987;10:254–8.
   PubMed Web of Science ®Google Scholar
• Midtbø K, Hals O. Serum ionized calcium—a predictor of therapeutic response to slow calcium channel blockade in essential hypertension. Angiology. 1987;38:841–6.
   PubMed Web of Science ®Google Scholar
• Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447:661–78.
   PubMed Web of Science ®Google Scholar
• Wang Y, O'Connell JR, McArdle PF, Wade JB, Dorff SE, Shah SJ, . Whole-genome association study identifies STK39 as a hypertension susceptibility gene. Proc Natl Acad Sci U S A. 2009;106:226–31.
   PubMed Web of Science ®Google Scholar
• Org E, Eyheramendy S, Juhanson P, Gieger C, Lichtner P, Klopp N, . Genome-wide scan identifies CDH13 as a novel susceptibility locus contributing to blood pressure determination in two European populations. Hum Mol Genet. 2009;18:2288–96.
   PubMed Web of Science ®Google Scholar
• Levy D, Ehret GB, Rice K, Verwoert GC, Launer LJ, Dehghan A, . Genome-wide association study of blood pressure and hypertension. Nat Genet. 2009;41:677–87.
   PubMed Web of Science ®Google Scholar
• Newton-Cheh C, Johnson T, Gateva V, Tobin MD, Bochud M, Coin L, . Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet. 2009;41:666–76.
   PubMed Web of Science ®Google Scholar
• Suonsyrjä T, Hannila-Handelberg T, Fodstad H, Donner K, Kontula K, Hiltunen TP. Renin-angiotensin system and alpha-adducin gene polymorphisms and their relation to responses to antihypertensive drugs: results from the GENRES study. Am J Hypertens. 2009;22:169–75.
   PubMed Web of Science ®Google Scholar
• Suonsyrjä T, Donner K, Hannila-Handelberg T, Fodstad H, Kontula K, Hiltunen TP. Common genetic variation of beta1- and beta2-adrenergic receptor and response to four classes of antihypertensive treatment. Pharmacogenet Genomics. 2010;20:342–5.
   PubMed Web of Science ®Google Scholar
• Donner KM, Hiltunen TP, Suonsyrjä T, Hannila-Handelberg T, Tikkanen I, Antikainen M, . CYP2C9 genotype modifies activity of the renin-angiotensin-aldosterone system in hypertensive men. J Hypertens. 2009;27:2001–9.
   PubMed Web of Science ®Google Scholar
• Arnett DK, Davis BR, Ford CE, Boerwinkle E, Leiendecker-Foster C, Miller MB, . Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study. Circulation. 2005;111:3374–83.
   PubMed Web of Science ®Google Scholar
• Davis BR, Arnett DK, Boerwinkle E, Ford CE, Leiendecker-Foster C, Miller MB, . Antihypertensive therapy, the alpha-adducin polymorphism, and cardiovascular disease in high-risk hypertensive persons: the Genetics of Hypertension-Associated Treatment Study. Pharmacogenomics J. 2007;7: 112–22.
   PubMed Web of Science ®Google Scholar
• Brugts JJ, Isaacs A, de Maat MP, Boersma E, van Duijn CM, Akkerhuis KM, . A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals. J Hypertens. 2011;29:509–19.
   PubMed Web of Science ®Google Scholar
• Donner KM, Hiltunen TP, Hannila-Handelberg T, Suonsyrjä T, Kontula K. STK39 variation predicts ambulatory blood pressure response to losartan in hypertensive men. Hypertension Res. 2012;35:107–14.
   PubMed Web of Science ®Google Scholar
• San-Cristobal P, Pacheco-Alvarez D, Richardson C, Ring AM, Vazquez N, Rafiqi FH, . Angiotensin II signaling increases activity of the renal Na-Cl cotransporter through a WNK4-SPAK-dependent pathway. Proc Natl Acad Sci U S A. 2009;106:4384–9.
   PubMed Web of Science ®Google Scholar
• Talati G, Ohta A, Rai T, Sohara E, Naito S, Vandewalle A, . Effect of angiotensin II on the WNK-OSR1/SPAK-NCC phosphorylation cascade in cultured mpkDCT cells and in vivo mouse kidney. Biochem Biophys Res Commun. 2010;393:844–8.
   PubMed Web of Science ®Google Scholar
• Rafiqi FH, Zuber AM, Glover M, Richardson C, Fleming S, Jovanović S, . Role of the WNK-activated SPAK kinase in regulating blood pressure. EMBO Mol Med. 2010; 2:63–75.
   PubMed Web of Science ®Google Scholar
• Duarte JD, Lobmeyer MT, Wang Z, Chapman AB, Gums JG, Langaee TY, . Lack of association between polymorphisms in STK39, a putative thiazide response gene, and blood pressure response to hydrochlorothiazide. Pharmacogenet Genomics. 2010;20:516–9.
   PubMed Web of Science ®Google Scholar
• Alderman MH, Cohen HW, Sealey JE, Laragh JH. Pressor responses to antihypertensive drug types. Am J Hypertens. 2010;23:1031–7.
   PubMed Web of Science ®Google Scholar